Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 7/20 | 0.72 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CES2 | O00748 | 4/20 | 0.67 |
| ▸ | CES1 | P23141 | 4/20 | 0.67 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lignoceric Acid SCHEMBL263640 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Heptadecanoic Acid SCHEMBL869759 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Dodecanoate SCHEMBL15220 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL5182562 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Decanoic Acid SCHEMBL518130 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Nonanoate SCHEMBL6902496 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Hexacosanoic Acid SCHEMBL10404707 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Behenic Acid SCHEMBL263324 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Myristic Acid SCHEMBL14167619 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Myristic Acid SCHEMBL8462979 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118738600-A | Zinc ion battery electrolyte for increasing entropy of ion solvation structure, preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-10-01 | — | — | CN | claimed |
| CN-117924789-A | Thermal expansion microsphere and preparation method and application thereof | 万华化学集团股份有限公司 | 2024-04-26 | — | — | CN | claimed |
| US-20230055665-A1 | DELIVERY CARRIER INTO CELL | ITO, KABUSIKIKAISYA (JP) | 2023-02-23 | — | — | US | claimed |
| US-11253450-B2 | Scalp care composition with improved stability | THE PROCTER & GAMBLE COMPANY | 2022-02-22 | — | — | US | claimed |
| CN-113194909-A | Scalp care compositions with improved stability | 宝洁公司 | 2021-07-30 | — | — | CN | claimed |
| US-10905744-B2 | Pharmaceutical formulations for the oral delivery of peptide drugs | CYPRUMED GMBH (AT) | 2021-02-02 | — | — | US | claimed |
| EP-3204045-B1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-12-05 | — | — | EP | claimed |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2018-10-04 | — | — | US | claimed |
| CN-108135962-A | For the pharmaceutical preparation of oral delivery peptide medicament | 塞浦路迈德有限责任公司 | 2018-06-08 | — | — | CN | claimed |
| WO-2018065634-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE NASAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-04-12 | — | — | WO | claimed |
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2017-10-26 | — | — | US | claimed |
| EP-3204045-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | Cyprumed GmbH (AT) | 2017-08-16 | — | — | EP | claimed |
| CN-106794252-A | Pharmaceutical formulations for oral delivery of peptide or protein drugs | 塞浦路迈德有限责任公司 | 2017-05-31 | — | — | CN | claimed |
| WO-2017060500-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2017-04-13 | — | — | WO | claimed |
| WO-2016055550-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2016-04-14 | — | — | WO | claimed |
| CN-101690698-B | Anti-dandruff hair conditioner composition | GUANGDONG MINGCHEN CO LTD | 2012-07-25 | — | — | CN | claimed |
| US-20110306729-A1 | CROSS-LINKING COMPOSITION IN THE FORM OF GRANULES FOR PREPARING CROSS-LINKED BITUMEN/ELASTOMER COMPOSITIONS | TOTAL RAFFINAGE MARKETING (FR) | 2011-12-15 | — | — | US | claimed |
| CN-101690698-A | Anti-dandruff hair conditioner composition | GUANGDONG MINGCHEN CO LTD | 2010-04-07 | — | — | CN | claimed |
| CN-100341408-C | Pyrithione antimicrobials enhanced with silver, copper or zinc ions | ARCH CHEM INC (US) | 2007-10-10 | — | — | CN | claimed |
| CN-1364056-A | Pyrithione biocides enhanced by silver, copper, or zinc ions | ARCH CHEM INC (US) | 2002-08-14 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | SLC30A5, SLC30A6, SON | FABP3 493/4885CA1 926/4885CES2 4318/4885 |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | SLC30A5, SLC39A11, SLC30A6 | FABP3 1228/4885CA1 386/4885CES2 4609/4885 |
| US-20230055665-A1 | DELIVERY CARRIER INTO CELL | CTSA, ATG4A, ATG7 | FABP3 2246/4885CA1 4432/4885CES2 1421/4885 |
| US-10905744-B2 | Pharmaceutical formulations for the oral delivery of peptide drugs | SLC30A5, SLC39A11, SLC30A6 | FABP3 1228/4885CA1 386/4885CES2 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.